Solventum (SOLV)
NYSEHealth CareMedical Instruments & SuppliesSnapshot 2026-07-08
$76.28-2.13%
Close 2026-07-07 · 1-day change
Reading SOLV? This analysis is rebuilt every market day. Get it tracked free. No credit card.
Track SOLV free→NYSEHealth CareMedical Instruments & SuppliesSnapshot 2026-07-08
Reading SOLV? This analysis is rebuilt every market day. Get it tracked free. No credit card.
Track SOLV free→QuarterlyIQ Insights · SOLV
Material updates from SEC filings (8-K, 10-Q, 10-K) ranked by impact, with no firehose noise.
Other Events. On May 10, 2024, Plaintiff Eric Gilbert (the “Plaintiff”), on behalf of a putative class of stockholders of Solventum Corporation (the “Company”), filed a Verified Class Action Complaint (the “Action”) in the Court of Chancery of the State of Delaware (the “Delaware Court”), challenging the validity of certain aspects of the advance notice and stockholder nomination provisions of the By-laws of the Company. On September 20, 2024, the Company modified the challenged provisions by…
The filing describes a new severance plan for certain employees, including executive officers.
hereof) 104 Cover Page Interactive Data File (the cover page XBRL tags are embedded in the Inline XBRL document). SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. SOLVENTUM CORPORATION By: /s/ Wayde McMillan Wayde McMillan Executive Vice President and Chief Financial Officer (Principal Financial Officer) Dated: May 5, 2026
Chief Accounting Officer — Mary Wilcox: Mary Wilcox intends to retire and resign after a successor is appointed.
hereof) 104 Cover Page Interactive Data File (the cover page XBRL tags are embedded in the Inline XBRL document). SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. SOLVENTUM CORPORATION By: /s/ Matthew M. Rice Matthew M. Rice Vice President, Associate General Counsel & Assistant Secretary Dated: February 26, 2026
hereof) 104 Cover Page Interactive Data File (the cover page XBRL tags are embedded in the Inline XBRL document). SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. SOLVENTUM CORPORATION By: /s/ Matthew M. Rice Matthew M. Rice Vice President, Associate General Counsel & Assistant Secretary Dated: November 6, 2025
Chief Commercial Officer — Heather Knight: Heather Knight was appointed to the newly created role of Chief Commercial Officer.
Completion of Acquisition or Disposition of Assets. On February 25, 2025, Solventum Corporation, a Delaware corporation (“Solventum”) and Thermo Fisher Scientific Inc., a Delaware corporation (“Buyer”), entered into a Transaction Agreement, pursuant to which Buyer agreed to acquire from Solventum certain assets and liabilities related to Solventum’s purification and filtration business. On June 25, 2025, Solventum and Buyer entered into an Amended and Restated Transaction Agreement (the “Agre…
Other Events. On August 22, 2025, Solventum Corporation (the “Company”) issued a press release announcing the commencement of cash tender offers (the “Tender Offers”) to purchase the Company’s outstanding notes of the series listed below for up to $1,750,000,000 aggregate purchase price. The Company is offering to purchase (i) its 5.450% Senior Notes due 2027 (the “2027 Notes”), 5.400% Senior Notes due 2029, 5.600% Senior Notes due 2034 and 5.450% Senior Notes due 2031 for an aggregate purcha…
hereof) 104 Cover Page Interactive Data File (the cover page XBRL tags are embedded in the Inline XBRL document). SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. SOLVENTUM CORPORATION By: /s/ Matthew M. Rice Matthew M. Rice Vice President, Associate General Counsel & Assistant Secretary Dated: August 7, 2025
Entry into a Material Definitive Agreement. As previously disclosed, on February 25, 2025, Solventum Corporation, a Delaware corporation (“Solventum”) and Thermo Fisher Scientific Inc., a Delaware corporation (“Buyer”), entered into a Transaction Agreement (the “Initial Agreement”), pursuant to which, subject to the satisfaction or waiver of certain conditions, Buyer agreed to acquire from Solventum certain assets and liabilities related to Solventum’s purification and filtration business. On…
hereof) 104 Cover Page Interactive Data File (the cover page XBRL tags are embedded in the Inline XBRL document). SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. SOLVENTUM CORPORATION By: /s/ Matthew M. Rice Matthew M. Rice Vice President, Associate General Counsel & Assistant Secretary Dated: May 8, 2025
Entry Into A Material Definitive Agreement. On February 25, 2025, Solventum Corporation, a Delaware corporation (“Solventum”) and Thermo Fisher Scientific Inc., a Delaware corporation (“Buyer”), entered into a Transaction Agreement (the “Agreement”). The Agreement provides that, subject to the satisfaction or waiver of certain conditions, Buyer will acquire from Solventum certain assets and the equity interests of certain entities constituting Solventum’s purification and filtration business…
hereof) 104 Cover Page Interactive Data File (the cover page XBRL tags are embedded in the Inline XBRL document). SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. SOLVENTUM CORPORATION By: /s/ Matthew M. Rice Matthew M. Rice Vice President, Associate General Counsel & Assistant Secretary Dated: February 27, 2025
hereof) 104 Cover Page Interactive Data File (the cover page XBRL tags are embedded in the Inline XBRL document). SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. SOLVENTUM CORPORATION By: /s/ Matthew M. Rice Matthew M. Rice Vice President, Associate General Counsel & Assistant Secretary Dated: November 7, 2024
The filing details a new severance plan for executives, not a change in management or departure.
hereof) 104 Cover Page Interactive Data File (the cover page XBRL tags are embedded in the Inline XBRL document). SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. SOLVENTUM CORPORATION By: /s/ Matthew M. Rice Matthew M. Rice Vice President, Associate General Counsel & Assistant Secretary Dated: August 8, 2024
The filing describes the approval of new forms of equity award agreements and details equity grants to executives, which is a routine compensation matter.
hereof) 104 Cover Page Interactive Data File (the cover page XBRL tags are embedded in the Inline XBRL document). SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. SOLVENTUM CORPORATION By: /s/ Matthew M. Rice Matthew M. Rice Vice President, Associate General Counsel & Assistant Secretary Dated: May 9, 2024
Director — Shirley A. Edwards: Ms. Shirley A. Edwards was elected to the Board of Directors and appointed to the Audit Committee and the Talent Committee.
Entry into a Material Definitive Agreement. Separation-Related Agreements On March 31, 2024, Solventum Corporation (“Solventum”) entered into several agreements with 3M Company (“3M”) in connection with the spin-off of 3M’s health care business (the “Separation”) through the pro rata distribution of 80.1% of the issued and outstanding shares of common stock, par value $0.01 per share, of Solventum to 3M’s stockholders of record as of the close of business on March 18, 2024 (the “Distribution”…
Material Modifications to Rights of Security Holders The information set forth under
Senior Vice President, Controller and Chief Accounting Officer; Executive Vice President and Group President of Solventum’s MedSurg business segment; Chief Information and Digital Officer; Chief Supply Officer; Chief Human Resources Officer — Mary Wilcox, Chris Barry, Amy Landucci, Paul Harrington, Tammy Gomez: Solventum has hired multiple senior executives from other companies to fill key roles.
Regulation FD Disclosure Information Statement Solventum Corporation (“Solventum”), a wholly owned subsidiary of 3M Company (“3M”), previously filed with the U.S. Securities and Exchange Commission a registration statement on Form 10 (as amended, the “Registration Statement”) relating to the planned distribution by 3M of 80.1% of the issued and outstanding shares of common stock, par value $0.01 per share, of Solventum (the “Solventum common stock”) to 3M shareholders. On March 13, 2024, the…
General market headlines, full earnings-call transcripts, and macro and sector developments flagged when they directly affect this stock are on the way. Today this tab covers SEC filings.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.